<DOC>
	<DOCNO>NCT00003249</DOCNO>
	<brief_summary>Phase I trial study effectiveness carboxyamidotriazole ketoconazole treat patient advanced cancer . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell .</brief_summary>
	<brief_title>Carboxyamidotriazole Ketoconazole Treating Patients With Advanced Cancers</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose carboxyamidotriazole ( CAI ) combination ketoconazole patient advanced malignancy . II . Evaluate toxic effect , safety , efficacy CAI combination ketoconazole . III . Determine modulatory effect ketoconazole pharmacokinetic profile CAI . IV . Determine pharmacodynamic model CAI ketoconazole respect potential gastrointestinal , hematologic , neurotoxicities . OUTLINE : This dose escalation study . Patients receive oral carboxyamidotriazole ( CAI ) test dose day 1 . Patients receive oral ketoconazole day 7 , follow CAI plus ketoconazole day 8 . CAI ketoconazole administer combination day 1 day 3-28 first course . Ketoconazole administer alone day 2 first course . Subsequent course begin 28 day interval absence disease progression unacceptable toxic effect . Cohorts 3 patient evaluate dose level prior dose escalation . If one three patient within cohort experience dose limit toxicity ( DLT ) , dose level expand incorporate six patient . If two patient experience DLT , next low dose declare maximum tolerated dose .</detailed_description>
	<mesh_term>Ketoconazole</mesh_term>
	<mesh_term>Carboxyamido-triazole</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven refractory recurrent nonhematologic malignancy Measurable evaluable disease radiographic clinical examination PATIENT CHARACTERISTICS : Age : 18 Performance Status : Karnofsky 70100 % Absolute neutrophil count least 2,000/mm3 Platelet count least 100,000/mm3 Bilirubin great 1.5 mg/dL SGOT SGPT great 2.5 time upper limit normal Albumin least 3 g/dL Creatinine great 1.5 mg/dL OR creatinine clearance great 60 mL/min No concurrent neurotoxicities great grade 1 previous chemotherapy No concurrent neuropathy great grade 1 Not pregnant Effective contraceptive method must use fertile patient 2 month study No serious uncontrolled medical illness No history active inflammatory bowel disease , ileus , chronic malabsorption syndrome PRIOR CONCURRENT THERAPY : No concurrent isoniazid No concurrent rifampin At least 4 week since chemotherapy At least 6 week since nitrosoureas therapy At least 3 month since suramin therapy No prior carboxyamidotriazole No concurrent steroid ( except dose require adrenal insufficiency ) No concurrent tamoxifen No prior radiotherapy within 4 week study No prior total gastrectomy total ileocolectomy No concurrent therapy H2 antagonist , barbiturate , calcium channel blocker , terfenadine , astemizole , cisapride , digitoxin , quinidine , amiodarone , carbamazepine , imipramine , antacids No concurrent erythromycin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>